Compare VRTX & SE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | SE |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Other Consumer Services |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8B | 58.7B |
| IPO Year | 2006 | 2017 |
| Metric | VRTX | SE |
|---|---|---|
| Price | $535.17 | $75.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 29 |
| Target Price | ★ $571.46 | $154.93 |
| AVG Volume (30 Days) | 1.1M | ★ 5.1M |
| Earning Date | 11-02-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 8.33 | N/A |
| Revenue | ★ $2,488,652,000.00 | N/A |
| Revenue This Year | $10.54 | $35.88 |
| Revenue Next Year | $9.74 | $22.88 |
| P/E Ratio | $64.00 | ★ $49.15 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $403.16 | $75.41 |
| 52 Week High | $560.25 | $164.03 |
| Indicator | VRTX | SE |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 17.95 |
| Support Level | $493.75 | N/A |
| Resistance Level | $531.78 | $99.26 |
| Average True Range (ATR) | 12.22 | 3.24 |
| MACD | 3.74 | -1.81 |
| Stochastic Oscillator | 84.09 | 2.20 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid consumer-to-consumer and business-to-consumer marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue-generating game. Sea's third business, Monee, provides lending, payment, digital banking, and insurance services. As of March 2025, Forrest Li, the founder, chair, and CEO, owned 59.1% of the voting power. Tencent owned 18.5% of issued shares with no voting power.